Schneyer Mark C.

EVP, CHIEF FINANCIAL OFFICERACADIA PHARMACEUTICALS INC (ACAD) · full profile →Form 4 · filed Aug 7, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$587K
Net Open-Market Flow
-$587K
Transactions
7
5 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 6, 2026Sell(S)5K$29.00$145K77K
Aug 6, 2026Option exercise(M)14K$17.84$255K82K
Aug 6, 2026Sell(S)9K$29.34$273K68K
Aug 5, 2026Option exercise(M)6K$17.84$104K74K
Aug 5, 2026Sell(S)6K$29.00$170K68K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 6, 2026Option exercise(M)14K$060K
Aug 5, 2026Option exercise(M)6K$075K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001899977-26-000008) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Build on these Form 4 transactions

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.